Daxor announces a strategic update to its regulatory approach for its novel diagnostic blood volume analyzer platform. Following productive discussions with the U.S. FDA, the company has decided to withdraw its current dual 510(k)/CLIA-waiver application and resubmit a focused 510(k) application. This decision comes after considerable progress in addressing key regulatory considerations and aims to expedite the approval process, potentially bringing this innovative technology to patients sooner. Daxor plans to pursue a separate CLIA-waiver application subsequently, allowing for a more targeted approach to each regulatory pathway. The company expects to submit the new 510(k) application in the coming quarter and will provide updates on its progress in the regulatory process, as appropriate.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR:
- Daxor announces review published in journal on BVA
- Daxor receives $300K matching fund award from Launch Tennessee
- Central Florida hospital implements Daxor BVA-100 blood volume diagnostic
- Daxor CEO says NAV increased to $6.75 p/s from $6.33 last year this time
- Daxor announces launch of BVA program at mid-south largest integrated network